Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00162110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00162110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
January 31, 2007
Enrollment
40
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mucinous gastrointestinal adenocarcinoma